Overview

Welcome to Dwaey, specifically on ZYNOPAT 0.2% Ophthalmic solution page.
This medicine contains an important and useful components, as it consists of Olopatadine Hydrochloride.
ZYNOPAT 0.2% is available in the market in concentration 2 mg/ml and in the form of Ophthalmic solution.

OMAN PHARMACEUTICAL PRODUCTS CO. L.L.C (ZYNOVA) is the producer of ZYNOPAT 0.2% and it is imported from OMAN, The most popular alternatives of ZYNOPAT 0.2% are listed downward .

Mode Of Action & Indication

Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.

Indication

• Allergic conjunctivitis

Precaution

Not intended for contact lens-related irritation. Pregnancy and lactation. Remove contact lenses prior to eye admin. Reinsert contact lenses 10 min after admin. Do not wear contact lenses if eyes are red. Improper handling may contaminate soln w/ bacteria that may cause ocular infections. Tip of the dispensing container should not be in contact w/ eye, eyelids or surrounding structures. Monitoring Parameters. Lactation: Unknown if distributed into breast milk; use caution

Side Effects

• 1-10% Headache (7%)
• Asthenia (<5%)
• Blurred vision (<5%)
• Burning or stinging (<5%)
• Cold syndrome (<5%)
• Dry eye (<5%)
• Foreign body sensation (<5%)
• Hyperemia (<5%)
• Hypersensitivity (<5%)
• Keratitis (<5%)
• Lid edema (<5%)
• Nausea (<5%)
• Pharyngitis (<5%)
• Pruritus (<5%)
• Rhinitis (<5%)
• Sinusitis (<5%)
• Taste perversion (<5%)

Contra indication

It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks